Sibutramine/Orlistat

PreclinicalSmall molecule

YYale University

Sibutramine/Orlistat is one of 8 small molecule programs targeting Binge Eating. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Binge EatingActive, not recruiting

Binge EatingPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Binge Eating

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Approved

2 2

Revia

Meridia

1 4

Topamax

WWim Janssens

Approved

—5

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 2

1 6

Lisdexamfetamine Dimesylate

Takeda

Preclinical

—7

GLP-1

RRigshospitalet, Denmark

Preclinical

1 8

Sibutramine/Orlistat

YYale University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Binge Eating1 trial

Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

Completed·YYale University·N/A·NCT00829283·191 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sibutramine/Orlistat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sibutramine/Orlistat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sibutramine/Orlistat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYale University

Sibutramine/Orlistat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Binge Eating1 trial

References

Drug Info

Quick Facts

Related News